DEPOMED INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Depomed, Inc. To Contact The Firm

NEW YORK, Aug. 8, 2017

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose Company activities that might have led to an investigation by the regulatory government authorities regarding its opioid products.

Specifically, during an investor call held post-market on August 7, 2017, the Company announced that on July 28, 2017 the Company received a subpoena from the Department of Justice and the office of the Attorney General of Maryland regarding its commercialization practices for its opioid products, NUCYNTA and Lazand. The Company reported that it "will be incurring legal expenses in support of [its] responses which are reflected in [its] updated guidance." On this news, the Company's stock price has declined.

If you invested in Depomed stock or options between and would like to discuss your legal rights, click here: www.faruqilaw.com/DEPO.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330